G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 99 filers reported holding G1 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,808,098 | -42.2% | 1,950,068 | 0.0% | 0.00% | – |
| Q2 2023 | $4,855,669 | -9.0% | 1,950,068 | -2.0% | 0.00% | – |
| Q1 2023 | $5,335,277 | -49.0% | 1,990,775 | +3.4% | 0.00% | – |
| Q4 2022 | $10,457,339 | -50.4% | 1,925,845 | +14.2% | 0.00% | -100.0% |
| Q3 2022 | $21,063,000 | +163.1% | 1,686,453 | +4.1% | 0.00% | – |
| Q2 2022 | $8,006,000 | -45.2% | 1,620,501 | -15.8% | 0.00% | – |
| Q1 2022 | $14,620,000 | -43.7% | 1,923,704 | -24.4% | 0.00% | -100.0% |
| Q4 2021 | $25,979,000 | -22.8% | 2,544,365 | +1.5% | 0.00% | 0.0% |
| Q3 2021 | $33,631,000 | -38.8% | 2,506,068 | +0.1% | 0.00% | 0.0% |
| Q2 2021 | $54,912,000 | -6.5% | 2,502,826 | +2.5% | 0.00% | -50.0% |
| Q1 2021 | $58,731,000 | +55.8% | 2,440,985 | +16.5% | 0.00% | +100.0% |
| Q4 2020 | $37,702,000 | +61.6% | 2,095,727 | +3.8% | 0.00% | 0.0% |
| Q3 2020 | $23,325,000 | -53.3% | 2,019,420 | -1.8% | 0.00% | -50.0% |
| Q2 2020 | $49,908,000 | +121.0% | 2,057,211 | +0.4% | 0.00% | +100.0% |
| Q1 2020 | $22,582,000 | -57.6% | 2,049,087 | +1.8% | 0.00% | -50.0% |
| Q4 2019 | $53,219,000 | +17.3% | 2,013,565 | +1.1% | 0.00% | 0.0% |
| Q3 2019 | $45,387,000 | -25.1% | 1,992,343 | +0.8% | 0.00% | 0.0% |
| Q2 2019 | $60,603,000 | +94.6% | 1,976,615 | +5.4% | 0.00% | +100.0% |
| Q1 2019 | $31,143,000 | -4.3% | 1,876,092 | +10.4% | 0.00% | 0.0% |
| Q4 2018 | $32,548,000 | -63.8% | 1,699,652 | -1.1% | 0.00% | -75.0% |
| Q3 2018 | $89,821,000 | +112.2% | 1,717,733 | +76.3% | 0.00% | +100.0% |
| Q2 2018 | $42,336,000 | +13.7% | 974,137 | -3.1% | 0.00% | 0.0% |
| Q1 2018 | $37,229,000 | +144.2% | 1,004,831 | +30.8% | 0.00% | +100.0% |
| Q4 2017 | $15,247,000 | +155.6% | 768,468 | +220.6% | 0.00% | – |
| Q3 2017 | $5,966,000 | +362.1% | 239,711 | +223.9% | 0.00% | – |
| Q2 2017 | $1,291,000 | – | 74,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 994,287 | $19,041,000 | 1.55% |
| HHLR ADVISORS, LTD. | 949,431 | $18,182,000 | 0.75% |
| BB BIOTECH AG | 671,925 | $12,867,000 | 0.41% |
| Rhenman & Partners Asset Management AB | 172,820 | $3,310,000 | 0.38% |
| Birchview Capital, LP | 15,000 | $287,000 | 0.27% |
| Rock Springs Capital Management LP | 100,000 | $1,915,000 | 0.09% |
| SECOR Capital Advisors, LP | 32,591 | $624,000 | 0.08% |
| MARSHALL WACE, LLP | 386,510 | $7,402,000 | 0.08% |
| SIGNATUREFD, LLC | 37,942 | $727,000 | 0.07% |
| A.R.T. Advisors, LLC | 38,125 | $730,000 | 0.05% |